Enimmune Corporation (TPEX:6564)
Taiwan · Delayed Price · Currency is TWD 18.95
0.00 (0.00%)
At close: May 8, 2026
Enimmune Market Cap
Enimmune has a market cap or net worth of 1.37 billion as of May 8, 2026. Its market cap has increased by 0.53% in one year.
Market Cap
1.37B
Enterprise Value
1.31B
Revenue
48.19M
Ranking
n/a
PE Ratio
n/a
Stock Price
18.95
Market Cap Chart
Since September 18, 2018, Enimmune's market cap has increased from 1.33B to 1.37B, an increase of 2.90%. That is a compound annual growth rate of 0.37%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 8, 2026 | 1.37B | -8.01% |
| Dec 31, 2025 | 1.49B | -17.27% |
| Dec 31, 2024 | 1.80B | -27.21% |
| Dec 29, 2023 | 2.47B | -38.63% |
| Dec 30, 2022 | 4.02B | 69.85% |
| Dec 30, 2021 | 2.37B | -11.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 26, 2018 | Upgrade Pro | Upgrade Pro |
| Sep 18, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Advagene Biopharma | 1.53B |
| GenMont Biotech Incorporation | 1.51B |
| NeoCore Technology | 1.40B |
| Abnova (Taiwan) | 1.33B |
| Bio Preventive Medicine | 1.33B |
| Meribank Biotech | 1.24B |
| BiOptic | 1.14B |
| Holy Stone Healthcare | 1.12B |